Scarica l'app Stockscreener
45.60
1.81%
0.81
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché EXEL Giù?
Forum
Previsione
Exelixis Inc Borsa (EXEL) Ultime notizie
Exelixis Inc. Stock Analysis and ForecastBreakthrough capital growth - PrintWeekIndia
10 Most Profitable Biotech Stocks to Invest in Now - Insider Monkey
Exelixis (EXEL) Q2 Earnings Preview: What to Expect - GuruFocus
Exelixis Q2 2025 Earnings Preview: Expectations and Performance - AInvest
What drives Exelixis Inc. stock priceFree Stock Chart Pattern Guide - PrintWeekIndia
Exelixis Advances Cancer Treatment with New Phase 1 Study of XB628 - TipRanks
Exelixis Gains Analyst Confidence as Cancer Studies Advances - MSN
EU approves cabozantinib for previously treated neuroendocrine tumors By Investing.com - Investing.com South Africa
Exelixis and Ipsen's Breakthrough Approval of CABOMETYX in Neuroendocrine Tumors: A Game Changer in a High-Growth Oncology Niche - AInvest
(cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors - Business Wire
Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner - MSN
Exelixis (EXEL) Gains EU Approval for Cabometyx in Neuroendocrine Tumors - GuruFocus
Ipsen wins EU nod for Exelixis cancer drug (EXEL:NASDAQ) - Seeking Alpha
Cabometyx® approved in the EU for previously treated advanced neuroendocrine tumors - GlobeNewswire Inc.
Citizens JMP Maintains Buy Rating on Exelixis with $50 Price Target - AInvest
Exelixis stock poised for Q2 beat on strong script growth, JMP says - Investing.com Canada
What analysts say about Exelixis Inc. stockExceptional growth trajectory - Autocar Professional
Exelixis Advances Cancer Studies with Rising Analyst Confidence - AInvest
Exelixis' Q2 Earnings: Will Cabometyx Sales Drive Growth? - TradingView
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance
What Analyst Projections for Key Metrics Reveal About Exelixis (EXEL) Q2 Earnings - Yahoo Finance
Is Exelixis Inc. a good long term investmentSuperior profit margins - jammulinksnews.com
Earnings Preview: Exelixis to Report Financial Results Post-market on July 28 - 富途牛牛
Is Exelixis, Inc.'s (NASDAQ:EXEL) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? - Yahoo Finance
Lobbying Update: $480,000 of EXELIXIS INC. lobbying was just disclosed - Quiver Quantitative
Morgan Stanley Maintains Exelixis(EXEL.US) With Buy Rating, Raises Target Price to $48 - 富途牛牛
Exelixis (EXEL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
Exelixis, Inc. (EXEL) Stock Analysis: Evaluating the 30.6% Revenue Growth and Future Prospects - DirectorsTalk Interviews
Teva Pharmaceutical Industries Limited shares fall 1.38% intraday after Exelixis, Inc. presents at Lucid Capital Markets. - AInvest
Exelixis Advances Cancer Treatment with New Phase 1 Study of XL309 - The Globe and Mail
Exelixis’s SWOT analysis: zanza trials key to stock’s future growth By Investing.com - Investing.com South Africa
Exelixis’s SWOT analysis: zanza trials key to stock’s future growth - Investing.com
Exelixis Insiders Sell US$12m Of Stock, Possibly Signalling Caution - simplywall.st
Long Term Trading Analysis for (EXEL) - news.stocktradersdaily.com
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Will Key Drugs Maintain Momentum for Novartis in Q2 Earnings? - The Globe and Mail
Truist Securities raises Exelixis stock price target to $56 on positive outlook - Investing.com Canada
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):